Cargando…
[(111)In]In-CP04 as a novel cholecystokinin-2 receptor ligand with theranostic potential in patients with progressive or metastatic medullary thyroid cancer: final results of a GRAN-T-MTC Phase I clinical trial
INTRODUCTION: Medullary thyroid cancer (MTC) is a rare malignant tumour of the parafollicular C-cells with an unpredictable clinical course and currently suboptimal diagnostic and therapeutic options, in particular in advanced disease. Overexpression of cholecystokinin-2 receptors (CCK2R) represents...
Autores principales: | Lezaic, Luka, Erba, Paola Anna, Decristoforo, Clemens, Zaletel, Katja, Mikolajczak, Renata, Maecke, Helmut, Maina, Theodosia, Konijnenberg, Mark, Kolenc, Petra, Trofimiuk-Müldner, Malgorzata, Przybylik-Mazurek, Elwira, Virgolini, Irene, de Jong, Marion, Fröberg, Alide C, Rangger, Christine, Di Santo, Gianpaolo, Skorkiewicz, Konrad, Garnuszek, Piotr, Solnica, Bogdan, Nock, Berthold A., Fedak, Danuta, Gaweda, Paulina, Hubalewska-Dydejczyk, Alicja |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9852173/ https://www.ncbi.nlm.nih.gov/pubmed/36334104 http://dx.doi.org/10.1007/s00259-022-05992-6 |
Ejemplares similares
-
Comparison of 99mTc radiolabeled somatostatin antagonist with [(68) Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor
por: Opalinska, Marta, et al.
Publicado: (2023) -
A novel CCK(2)/gastrin receptor-localizing radiolabeled
peptide probe for personalized diagnosis and therapy of patients with
progressive or metastatic medullary thyroid carcinoma: a multicenter phase I
GRAN-T-MTC study
por: Erba, Paola A., et al.
Publicado: (2018) -
Clinical translation of theranostic radiopharmaceuticals: Current regulatory status and recent examples
por: Kolenc Peitl, Petra, et al.
Publicado: (2019) -
Modifier Role of Common RET Variants in Sporadic Medullary Thyroid Carcinoma
por: Skalniak, Anna, et al.
Publicado: (2021) -
Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with (111)In-CP04 in medullary thyroid carcinoma patients
por: Maina, Theodosia, et al.
Publicado: (2016)